Alcidion Expands Patient Flow Business with Kyra Acquisition From Telstra Health

Why It Matters

The acquisition accelerates Alcidion’s move toward recurring‑revenue models and expands its patient‑flow footprint, strengthening its competitive position in a market increasingly driven by AI‑enabled clinical tools.

Key Takeaways

• Alcidion pays $2 M cash for Kyra suite, adds $2.4 M FY26 revenue.
• Acquisition adds 33 customers, only two were existing Alcidone clients.
• FY26 EBITDA multiple is 2.7×, implying $0.73 M EBITDA.
• Earn‑out up to $0.66 M tied to 12‑month revenue targets.
• Miya AI gains Class I SaMD clearance in Australia, UK.

Pulse Analysis

Alcidion’s $2 million cash acquisition of Telstra Health’s Kyra suite marks a decisive step toward bolstering its recurring‑revenue base. By integrating Kyra’s Patient Flow Manager, Queue Manager, and IQ analytics, Alcidion expects to generate roughly $2.4 million in FY26 revenue, with more than 90% recurring. The deal’s implied EBITDA multiple of 2.7× translates to about $0.73 million of underlying earnings, positioning the transaction as earnings‑accretive and reinforcing the company’s guidance for FY26 revenue above $33 million and EBITDA exceeding $3.3 million.

Beyond the financial metrics, the acquisition expands Alcidion’s customer footprint to 33 new health‑care organizations across Queensland, Victoria, Western Australia, and Tasmania. With only two of these clients already on Alcidion’s platform, the firm gains a substantial cross‑selling runway, especially in inpatient and outpatient patient‑flow optimization. The added customer base diversifies revenue streams and deepens market penetration in both public and private sectors, a critical advantage as hospitals seek integrated digital solutions to improve throughput and reduce wait times.

The timing aligns with Alcidion’s recent regulatory win for its Miya Precision Concept Detection AI, which secured Class I SaMD clearance in Australia and the United Kingdom. This approval unlocks compliant deployment of AI‑driven documentation and decision‑support tools in the company’s two largest markets, creating upsell pathways for existing and newly acquired clients. Together, the Kyra acquisition and AI clearance position Alcidion to capture a larger share of the growing patient‑flow and AI‑enabled health‑tech market, driving sustainable growth and shareholder value.